ArticleHuman vaccines & immunotherapeutics2026
Strategies used to improve immunization coverage of nirsevimab in an autonomous community in Spain.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study.European journal of pediatrics · 2026Observational
- Regional, altitudinal, and age-specific heterogeneity of bronchiolitis hospitalization seasonality in Ecuador, 2007-2024, and implications for RSV immunoprophylaxis timing.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, particularly in infants under one year. In 2023, Spain became one of the first countries to implement nirsevimab, a long-acting monoclonal antibody, for RSV prevention. This study evaluates the second immunization campaign in the Region of Murcia, focusing on coverage, timeliness, and equity. A retrospective cross-sectional analysis included children born between April 2024 and March 2025. Coverage was assessed for infants born during and outside the RSV season. Continuous training for healthcare professionals and targeted family education were implemented to improve uptake. Of 12,606 children, 11,785 (93.5%) received nirsevimab, with coverage higher for those born during the campaign (96.0%) than before (90.5%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.